Press Releases

Print Page   Print Page       E-mail Page   Email Page       RSS Feeds   RSS       E-mail Alerts  Email Alerts       Financial Tear Sheet  Tear Sheet

Press Releases

Date Title
04/26/18 Alkermes Plc Reports First Quarter 2018 Financial Results
04/19/18 Alkermes to Host Conference Call to Discuss First Quarter 2018 Financial Results
04/16/18 Alkermes Announces FDA Acceptance for Review of New Drug Application for ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder
04/02/18 Alkermes Receives Refusal to File Letter From FDA for ALKS 5461
03/05/18 Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences
03/01/18 Alkermes Appoints James Robinson as President and Chief Operating Officer
02/14/18 Alkermes Appoints Shane Cooke to Board of Directors
02/14/18 Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2017 and Provides Financial Expectations for 2018
02/07/18 Alkermes To Host Conference Call To Discuss Fourth Quarter And Year-End 2017 Financial Results
01/31/18 Alkermes Submits New Drug Application To U.S. FDA For ALKS 5461 For The Adjunctive Treatment Of Major Depressive Disorder
01/02/18 Alkermes' Corporate Presentation to be Webcast at the 36th Annual J.P. Morgan Healthcare Conference
11/27/17 Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis
11/20/17 Alkermes Named a Top Place to Work by The Boston Globe
11/16/17 Alkermes’ New Drug Application for Investigational Product Designed for Initiation Onto ARISTADA® Accepted for Filing by U.S. FDA
11/14/17 VIVITROL® and Value of Medication-Assisted Treatment for Opioid Dependence Featured in Study Sponsored by National Institute on Drug Abuse
Displaying 121 - 135 of 795